   #alternate alternate

   We use cookies to understand how visitors search for and consume the
   information we provide, so that we can improve their experience. By
   browsing this website, you indicate your acceptance of the use of such
   cookiesAcceptRead more

   Direct accesses
     * Go to main menu
     * Go to main content

   (BUTTON)
   Menu
   GenSight GenSight
   Search the site

     * Contact
     * Careers

     * You are viewing the website in English en
     * fr

     *

   Search the site
     * Whowe are
          + Company
          + Leadership
          + Collaborations
     * Our products& pipeline
          + Diseases we target
          + GS010 for LHON
          + GS030 for Retinitis Pigmentosa
          + GS030 for Geographic Atrophy in Dry-AMD
     * Ourtechnologies
          + Technologies we are applying
          + Gene Therapy
          + Mitochondrial Targeting Sequence (MTS)
          + Optogenetics
     * Investors& media
          + Company Overview
          + Press releases
          + Events & presentations
          + Stock information
          + Governance
          + Documentation

Leading the Use of Gene Therapy
Against Blindness

   (BUTTON) Pause
     * (BUTTON) Move to carousel item 1
     * (BUTTON) Move to carousel item 2
     * (BUTTON) Move to carousel item 3
     * (BUTTON) Move to carousel item 4
     * (BUTTON) Move to carousel item 5
     * (BUTTON) Move to carousel item 6

   [gensight-biologics-mitochondria-2-820x700.jpg]
   [Imagerescue-2-390x230.png]
   GS010: Sustained and Positive Efficacy at 96-Weeks of the RESCUE Phase
   III clinical trial
   Replay the Webcast & Conference call
   More details
   [gensight-biologics-office_09-4-820x700.jpg]
   [gensight-biologics-22-390x304.jpg]
   GS010: Positive 96w data from REVERSE Phase III clinical trial
   Replay Webcast & Conference call
   Get all details
   [gensight-biologics-neurons-1-820x700.jpg]
   [Pioneer-2-1-390x304.jpg]
   GS030 PIONEER Phase I/II: Positive DSMB review and continuation of the
   study
   Read More
   [img-gensight-1-820x700.jpg]
   [iStock-450853983-390x304.jpg]
   We are developing therapies to preserve or restore vision in patients
   suffering from neurodegenerative retinal diseases
   Our mission
   [gensight-biologics-large-image-GS010-slide-820x700.jpg]
   [gensight-biologics-mitochondria-1-390x304.jpg]
   Our product candidate GS010 is in clinical trials to treat LHON
   patients with the ND4 gene mutation
   More on GS010 in LHON
   [gensight-biologics-large-image-GS030-slide-1-820x700.jpg]
   [gensight-biologics-neurons-3-390x304.jpg]
   Our product candidate GS030 just entered its Phase I/II clinical trial
   after showing promising results in preclinical investigations
   More on GS030 in RP

Our products and pipeline

     * GS010
       Gene Therapy + MTS
       Leber Hereditary Optic Neuropathy (LHON)
     * GS030
       Gene Therapy + Optogenetics
       Retinitis Pigmentosa (RP)
     * GS030
       Gene Therapy + Optogenetics
       Geographic Atrophy in Dry-AMD

     * View Our products & Pipeline

   [gensight-biologics-11b-1.jpg]

Clinical trials

   GS010 is in Phase III trials while GS030 has begun Phase I/II
   Check status

Our technologies

     * [gensight-biologics-helix-1-480x320.jpg]
       Gene Therapy
     * [gensight-biologics-mitochondria-2-480x320.jpg]
       Mitochondrial Targeting Sequence (MTS)
     * [gensight-biologics-neurons-2-480x320.jpg]
       Optogenetics

     * View our Technologies

News & Media

     * Press releases
     * Events & presentations

   09 October 2019
   GenSight Biologics reports evidence of GS010 DNA transfer to
   contralateral eye of primates unilaterally injected with GS010 Gene
   Therapy
   08 October 2019
   GenSight Biologics Appoints Magali Taiel as Chief Medical Officer
   08 October 2019
   GenSight Biologics to present new GS010 data at the 2019 Annual Meeting
   of the American Academy of Ophthalmology
   All Press releases
   12 Oct 2019 - 15 Oct 2019
   American Academy of Ophthalmology, San Francisco (CA)
   10 Oct 2019
   Ophthalmology Innovation Summit @ AAO, San Francisco (CA)
   09 Oct 2019
   Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco
   (CA)
   All Events & presentations

     * Paris
     * New York City

   GENSIGHT BIOLOGICS S.A.
   74, rue du Faubourg Saint-Antoine
   75012 Paris
   FRANCE
   +33 1 76 21 72 20
   Contact us
   GENSIGHT BIOLOGICS Inc.
   3 East 28th Street
   New York, NY 10016
   USA
   +1 (332) 877-0670
   Contact us

   © 2019 Gensight Biologics
     * Terms of use
     * Sitemap
     * Contact
     * Credits

     *
     *
     *

   Go back to the page of the page
   #alternate alternate

   We use cookies to understand how visitors search for and consume the
   information we provide, so that we can improve their experience. By
   browsing this website, you indicate your acceptance of the use of such
   cookiesAcceptRead more

   Direct accesses
     * Go to main menu
     * Go to main content

   (BUTTON)
   Menu
   GenSight GenSight
   Search the site

     * Nous contacter
     * Carrières

     * en
     * You are viewing the website in Français fr

     *

   Search the site
     * Quisommes-nous ?
          + La société
          + Equipe dirigeante
          + Collaborations
     * nos produits& notre pipeline
          + Maladies ciblées
          + GS010 pour NOHL
          + GS030 pour la Rétinite Pigmentaire (RP)
          + GS030 pour l’Atrophie Géographique (GA) de la DMLA sèche
     * Nostechnologies
          + Plate-formes technologiques
          + Thérapie génique
          + Séquence de ciblage mitochondrial (MTS)
          + Optogénétique
     * Investisseurs& Media
          + Présentation générale
          + Communiqués de presse
          + Evenements
          + Données boursières
          + Gouvernance
          + Documentation

Leader de la thérapie génique
contre la cécité

   (BUTTON) Pause
     * (BUTTON) Move to carousel item 1
     * (BUTTON) Move to carousel item 2
     * (BUTTON) Move to carousel item 3
     * (BUTTON) Move to carousel item 4
     * (BUTTON) Move to carousel item 5
     * (BUTTON) Move to carousel item 6

   [gensight-biologics-mitochondria-2-820x700.jpg]
   [image-rescue-3.png]
   GS010 : efficacité et sécurité prolongées à 96 semaines de l’étude
   clinique de Phase III RESCUE
   Revoir la conférence téléphonique et le webcast
   En savoir plus
   [gensight-biologics-office_09-4-820x700.jpg]
   [gensight-biologics-22-390x304.jpg]
   GS010 : résultats positifs à 96 semaines de l’étude clinique de Phase
   III REVERSE
   Revoir le Webcast et la conférence téléphonique
   En savoir plus
   [gensight-biologics-neurons-1-820x700.jpg]
   [Pioneer-2-1-390x304.jpg]
   GS030 étude clinique PIONEER de Phase I/II : conclusions positives du
   DSMB et poursuite de l'étude
   En savoir plus
   [img-gensight-1-820x700.jpg]
   [iStock-450853983-390x304.jpg]
   Nous développons des thérapies pour préserver ou restaurer la vision
   chez des patients souffrant de maladies neurodégénératives de la rétine
   Notre mission
   [gensight-biologics-large-image-GS010-slide-820x700.jpg]
   [gensight-biologics-mitochondria-1-390x304.jpg]
   Notre produit candidat GS010 est en développement clinique pour traiter
   les patients atteints de NOHL avec la mutation du gène ND4
   En savoir plus sur GS010 dans la NOHL
   [gensight-biologics-large-image-GS030-slide-1-820x700.jpg]
   [gensight-biologics-neurons-3-390x304.jpg]
   Notre produit candidat GS030 entre maintenant en essai clinique de
   phase I/II après avoir montré des résultats prometteurs lors des études
   précliniques
   En savoir plus sur GS030 dans la RP

nos products et notre pipeline

     * GS010
       Thérapie génique + MTS
       Neuropathie Optique Héréditaire de Leber (NOHL)
     * GS030
       Thérapie génique + Optogenetique
       Rétinite Pigmentaire (RP)
     * GS030
       Thérapie génique + Optogenetique
       Atrophie Géographique de la DMLA sèche

     * Voir nos produits & notre pipeline

   [gensight-biologics-11b-1.jpg]

Essais cliniques

   GS010 est en étude clinique de phase III tandis que GS030 a commencé la
   phase I/II
   Vérifier l'avancement clinique

nos technologies

     * [gensight-biologics-helix-1-480x320.jpg]
       Thérapie génique
     * [gensight-biologics-mitochondria-2-480x320.jpg]
       Séquence de Ciblage Mitochondrial (MTS)
     * [gensight-biologics-neurons-2-480x320.jpg]
       Optogénétique

     * Voir nos Technologies

Actualités et Médias

     * Communiqués de presse
     * Evenements

   09 octobre 2019
   GenSight Biologics met en évidence le passage de l’ADN du GS010 dans
   l’œil controlatéral chez des primates ayant reçu une injection
   unilatérale de la thérapie génique GS010
   08 octobre 2019
   GenSight Biologics nomme Magali Taiel au poste de Directeur Médical
   08 octobre 2019
   GenSight Biologics présentera de nouveaux résultats de GS010 au Congrès
   Annuel 2019 de l’American Academy of Ophthalmology
   Tous Communiqués de presse
   12 Oct 2019 - 15 Oct 2019
   American Academy of Ophthalmology, San Francisco (CA)
   10 Oct 2019
   Ophthalmology Innovation Summit @ AAO, San Francisco (CA)
   09 Oct 2019
   Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco
   (CA)
   Tous Evenements

     * Paris
     * New York City

   GENSIGHT BIOLOGICS PARIS
   74, rue du Faubourg Saint-Antoine
   75012 Paris
   FRANCE
   +33 1 76 21 72 20
   Nous contacter
   GENSIGHT BIOLOGICS NYC
   765 Fifth Avenue, 14th floor
   New York, NY 10017
   USA
   +1 212-336-1440
   Nous contacter

   © 2019 Gensight Biologics
     * Conditions d’utilisations
     * Plan du site
     * Nous contacter
     * Crédits

     *
     *
     *
     *

   Retourner en haut de la page
   #alternate

   We use cookies to understand how visitors search for and consume the
   information we provide, so that we can improve their experience. By
   browsing this website, you indicate your acceptance of the use of such
   cookiesAcceptRead more

   Direct accesses
     * Go to main menu
     * Go to main content

   (BUTTON)
   Menu
   GenSight GenSight
   Search the site

     * Contact
     * Careers

     * You are viewing the website in English en
     * fr

     *

   Search the site
     * Whowe are
          + Company
          + Leadership
          + Collaborations
     * Our products& pipeline
          + Diseases we target
          + GS010 for LHON
          + GS030 for Retinitis Pigmentosa
          + GS030 for Geographic Atrophy in Dry-AMD
     * Ourtechnologies
          + Technologies we are applying
          + Gene Therapy
          + Mitochondrial Targeting Sequence (MTS)
          + Optogenetics
     * Investors& media
          + Company Overview
          + Press releases
          + Events & presentations
          + Stock information
          + Governance
          + Documentation

AAO, November 14-17, 2015, Las Vegas (CA), US

   14 Nov 2015 - 17 Nov 2015
     * Events & presentations

   GenSight Biologics participated to AAO in Las vegas, US.

   Jose Alain Sahel MD, CHNO Institut de la Vision, GenSight-Biologics
   Share Holder and Consultant, gave an oral presentation (Abstract ID:
   30043757) : A Recombinant AAV2/2 Vector Carrying the Wild-Type ND4 Gene
   for the Treatment of Leber Hereditary Optic Neuropathy: Results of a
   First-in-Human Study on Tuesday, November 17, 2015, 9:30 AM to 9:40 AM,
   location Bassano 2701.


   Back to list

   © 2019 Gensight Biologics
     * Terms of use
     * Sitemap
     * Contact
     * Credits

     *
     *
     *

   Go back to the page of the page
